Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection

Annals of Surgical Oncology

Volumn 23, Issue 1, 2016, Pages 235-243

  Spolverato, Gaya ^a   Kim, Yuhree ^a   Alexandrescu, Sorin ^b   Marques, Hugo P ^c   Lamelas, Jorge ^c   Aldrighetti, Luca ^d   Clark Gamblin, T ^e   Maithel, Shishir K ^f   Pulitano, Carlo ^g   Bauer, Todd W ^h   Shen, Feng ⁱ   Poultsides, George A ^j   Tran, Thuy B ^j   Wallis Marsh, J ^k   Pawlik, Timothy M ^a,l  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c HOSPITAL CURRY CABRAL   (Portugal)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^j STANFORD UNIVERSITY   (United States)

^k UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^l JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ABLATION THERAPY; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMIHEPATECTOMY; HUMAN; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERINEURAL INVASION; POSTOPERATIVE COMPLICATION; TREATMENT OUTCOME; TUMOR INVASION; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE MANAGEMENT; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COHORT STUDIES; DISEASE MANAGEMENT; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 84952631066     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4642-9     Document Type: Article

References (28)

1. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009;208(1):134–47.
2. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB. 2008;10(2):77–82.
3. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.
4. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33(6):1353–7.
5. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014. doi:10.1001/jamasurg.2013.5137.
6. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193(4):384–91.
7. Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik TM. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol. 2014;110(2):163–70. doi:10.1002/jso.23605.
8. Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254(5):824–9; discussion 830.
9. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.
10. Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection. Updates Surg. 2010;62(1):11–9.
11. Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepato-gastroenterol. 2012;59(118):1765–8.
12. Hanazaki K, Kajikawa S, Shimozawa N, et al. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepato-gastroenterol. 2002;49(44):311–6.
13. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.
14. Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006;41(9):893–900.
15. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811–8.
16. Kneuertz PJ, Cosgrove DP, Cameron AM, et al. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012;16(4):874–81.
17. de Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg. 2009;13(12):2141–51.
18. Maeda T, Hashimoto K, Ishida T, et al. Repeat hepatectomy for intrahepatic recurrence of cholangiolocellular carcinoma. Fukuoka igaku zasshi = Hukuoka acta medica. 2013;104(12):564–8.
19. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual (7th edn). 2010.
20. Mayo SC, Shore AD, Nathan H, et al. Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB. 2011;13(7):473–82.
21. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
22. Arnaoutakis DJ, Mavros MN, Shen F, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol. 2014;21(1):147–54.
23. Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219(4):664–75. doi:10.1016/j.jamcollsurg.2014.03.062.
24. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–8.
25. Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Surg. 2014;18(12):2136–48.
26. Adachi T, Eguchi S, Beppu T, et al. Prognostic impact of preoperative lymph node enlargement in intrahepatic cholangiocarcinoma: a multi-institutional study by the Kyushu Study Group of Liver Surgery. Ann Surg Oncol. 2015;22:2269–78. doi:10.1245/s10434-014-4239-8.
27. Guglielmi A, Ruzzenente A, Campagnaro T, et al. Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17(11):1917–28.
28. Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779–86.